Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,164.65 +23.20 (+2.03%)
Streaming Delayed Price Updated: 2:57 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 243,111
Open 1,138.10
Bid (Size) 1,164.01 (2)
Ask (Size) 1,164.98 (1)
Prev. Close 1,141.45
Today's Range 1,127.20 - 1,164.78
52wk Range 769.19 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Via Benzinga
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints. 
Via Benzinga

Performance

YTD
+28.69%
+28.69%
1 Month
+3.89%
+3.89%
3 Month
+13.33%
+13.33%
6 Month
+20.63%
+20.63%
1 Year
+39.85%
+39.85%

More News

Read More
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
Via News Direct
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
Via Benzinga
Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock
Via Benzinga
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
Via Benzinga
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
Via Benzinga
Prediction: These 2 Companies Will Split Their Stocks by 2027
Via The Motley Fool
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
Via Benzinga
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Via Benzinga
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
Via The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
Via Talk Markets
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
10 Bagger Stocks: Can You Find One?
Via Talk Markets
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
Via Benzinga
Exposures Product Safety
Regeneron Provides Update on Biologics License Application for Linvoseltamab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
Alphabet Turns Twenty
Via Talk Markets
7 Stocks That Usually Benefit From a Recession
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.